Glp 1
7 articles
Peptide craze hype faces scientific and practical hurdles
Only 1 in 12 patients prescribed GLP-1 treatment remain on the medication after three years, according to data from Prime Therapeutics .
Medicare offers $50 monthly GLP-1 access amid obesity drug competition
Starting July 1, 2026, eligible Medicare beneficiaries will pay just $50 a month for certain GLP-1 obesity drugs.
Pfizer's obesity drug shows potential for monthly dosing
Mid-stage study data reveals Pfizer's experimental obesity drug, berobenatide, could achieve significant weight loss with a groundbreaking monthly dosing schedule, a stark contrast to current weekly o
Lilly's oral obesity drug shows promising safety and tolerability
Lilly's experimental oral obesity drug, aleniglipron, helped patients lose up to 12.
Medicare Unveils $50 Monthly Cap on Obesity Drugs
Starting in July, eligible Medicare beneficiaries will access GLP-1 weight-loss medications for a monthly cost of just $50, according to The Motley Fool .
New Study Revisits Brain Theory and Neuroscience Concepts
Researchers recently pinpointed that the weight-loss effects of the GLP-1 drug semaglutide hinge on increased levels of a single molecule, cyclic adenosine monophosphate (cAMP), in a specific brain re
New Quintuple Agonist Targets GLP-1R, GIPR, PPARs in Mice
In mouse models, an experimental obesity and diabetes drug called GLP-1-GIP-Lani not only corrected obesity and diabetes but also significantly outperformed semaglutide in lowering body weight, food i